Citigroup Begins Coverage on Medtronic (NYSE:MDT)

Research analysts at Citigroup started coverage on shares of Medtronic (NYSE:MDT) in a note issued to investors on Tuesday. The firm set a “buy” rating and a $117.00 price target on the medical technology company’s stock. Citigroup’s target price suggests a potential upside of 14.92% from the stock’s current price.

MDT has been the subject of a number of other research reports. Morgan Stanley raised their price objective on shares of Medtronic from $107.00 to $117.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 19th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $110.00 target price on shares of Medtronic in a research report on Wednesday, November 19th. CICC Research assumed coverage on Medtronic in a report on Friday, January 30th. They set an “outperform” rating on the stock. Robert W. Baird set a $103.00 price objective on Medtronic in a research note on Tuesday, December 16th. Finally, Wall Street Zen upgraded Medtronic from a “hold” rating to a “buy” rating in a research report on Friday, January 23rd. Fifteen analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $110.67.

Medtronic Trading Down 1.3%

Shares of MDT opened at $101.81 on Tuesday. The business’s 50-day moving average price is $99.48 and its 200 day moving average price is $95.96. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57. The stock has a market capitalization of $130.52 billion, a P/E ratio of 27.44, a P/E/G ratio of 2.72 and a beta of 0.71. Medtronic has a 1-year low of $79.55 and a 1-year high of $106.33.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, beating analysts’ consensus estimates of $1.31 by $0.05. The company had revenue of $8.96 billion during the quarter, compared to analyst estimates of $8.86 billion. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The business’s quarterly revenue was up 6.6% on a year-over-year basis. During the same period in the prior year, the firm earned $1.26 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Analysts expect that Medtronic will post 5.46 earnings per share for the current year.

Hedge Funds Weigh In On Medtronic

A number of hedge funds have recently added to or reduced their stakes in MDT. Corundum Trust Company INC acquired a new position in shares of Medtronic during the 3rd quarter worth $27,000. Lodestone Wealth Management LLC bought a new stake in Medtronic in the fourth quarter worth $27,000. Anfield Capital Management LLC boosted its holdings in Medtronic by 410.7% in the fourth quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 230 shares in the last quarter. Board of the Pension Protection Fund acquired a new position in Medtronic during the fourth quarter worth $29,000. Finally, GoalVest Advisory LLC bought a new position in Medtronic during the fourth quarter valued at about $29,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic will exercise its option to acquire CathWorks for up to $585 million, adding AI-enabled coronary imaging/diagnostics to its interventional cardiology and cath-lab portfolio — a clear strategic bolt-on that could expand addressable market and recurring software/diagnostic revenues. Medical device maker Medtronic to buy CathWorks in up to $585 million deal Medtronic advances its innovation strategy with intent to acquire CathWorks
• Positive Sentiment: New analyst coverage: Citigroup started coverage with a Buy rating and $117 price target (roughly mid-teens upside from current levels), which can support renewed investor demand and higher price targets among peers.
• Positive Sentiment: Recent quarterly results showed an earnings beat and management set FY26 EPS guidance in the $5.62–$5.66 range, signaling durable margins and cash flow that underpin dividend safety and buyback capacity.
• Positive Sentiment: Dividend/quality narrative remains supportive: coverage highlighting Medtronic as a reliable dividend healthcare pick reinforces interest from income-oriented investors. 2 Healthcare Dividend Stocks That are Just What the Doctor Ordered
• Neutral Sentiment: Company messaging and product launch activity emphasize expansion of heart and diabetes tools, but a recent article notes Medtronic’s valuation is approaching analyst targets — suggesting limited near-term upside unless acceleration in top-line or margin improvement shows up. Medtronic Expands Heart And Diabetes Tools As Valuation Nears Analyst Views
• Negative Sentiment: Leadership change: Nina Goodheart, President of Structural Heart, is retiring — a near-term governance/operational uncertainty for a key growth business that could weigh on sentiment until succession clarity is provided. Medtronic Structural Heart President Nina Goodheart to retire

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).